Genmab — November 2019
-
-
Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis https://link.springer.com/article/10.1007/s00467-019-04365-w full art http://sci-hub.tw/https://link.springer.com/article/10.1007/s00467-019-04365-w
-
-
repeating a link from yesterday; the CD123 x CD3 DuoBody increased Enrollment from 60 to 120 (which gives me some new hope on this trial) https://clinicaltrials.gov/ct2/history/NCT02715011?A=28&B=29&C=merged#StudyPageTop
-
peter12: Der forskes i hvert fald i det andre steder, men om andre firmaer har en decideret hexamerizations-platform ved jeg ikke. Måske Sukkeralf? https://www.ncbi.nlm.nih.gov/pubmed/28578024
-
-
Vi fik i går at vide at IMS' salgstal (39mio$ gns pr uge i oktober) er bruttotal før rabatter. SH's tal ligger ca 14% over JnJ's. Hvis vi antager det samme for IMS får vi nettosalg på 33,5mio$ pr uge i oktober. Hvis us ikke stiger yderligere i nov og dec skal row stige 18% fra q3 til q4.
-
-
-
Jeg mener David nævnte at italien var kommet med på dara for nylig ? Så lige at Velcade kan fås generisk fra Q2 https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2019/files/infographic/market_acces_phase2_infographic.pdf
-
Peter12 der findes i hvert fald mange teknologier/platforme til at forbedre effector functions - og synes altid Genmab har haft særlig meget fokus på CDC. Kigger man i nedenstående link tabel 8, så lader det til at dannelse af hexamere er relativ nyt:
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind